|
Sir Tom was appointed a non-executive director of BP in 2004. He is a member of the chairman’s, the remuneration, and the safety, ethics and environment assurance committees.
Following post-doctorate research work in chemistry in Paris, Sir Tom joined ICI’s corporate research laboratory in 1969, where his research covered synthetic chemistry, quantum mechanics and molecular biology. In 1975, he joined ICI’s pharmaceuticals division as head of natural products research. In 1978, he returned to France as research director of ICI’s French pharmaceuticals division. On his return to the UK, he held a number of positions in ICI Pharmaceuticals in chemistry and research and development between 1980 and 1989. In 1989, he became technical director of ICI Pharmaceuticals with international responsibility for research, development and production. Following the demerger of Zeneca Group PLC from ICI PLC, in 1994 he became chief executive officer of Zeneca Pharmaceuticals and, in 1996, he was appointed to the board of Zeneca Group PLC as an executive director. Sir Tom was chief executive of AstraZeneca PLC from the merger of Astra AB and Zeneca Group PLC in 1999 until 2005. Sir Tom is chairman of The Royal Bank of Scotland Group plc and was a non-executive director of Lloyds TSB Group PLC until 2004. He is a non-executive director of Almirall Prodesfarma. He is a fellow of the Royal Society, president of The Science Council, and a trustee of the Council for Industry and Higher Education. Sir Tom was knighted in 2002. | 